Products for Research Use Only

(+) -Cevimeline hydrochloride hemihydrate

CAT: 0931-T13460-01Size: 100 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0931-T13460-01Size:100 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Target
Others, AChR
Related Pathways
Others, Neuroscience
Bioactivity
(+) -Cevimeline hydrochloride hemihydrate ((+) -SNI-2011), a potent muscarinic receptor agonist, shows promise as a therapeutic candidate for xerostomia in Sjogren's syndrome. It exhibits a broad pharmacological profile across various systems in animal models including mice, rats, guinea pigs, rabbits, and dogs. Metabolism studies using rat and dog liver microsomes reveal rapid absorption with peak plasma concentrations (Cmax) within one hour post-oral administration and a half-life (t1/2) between 0.4 to 1.1 hours. Bioavailability is 50% in rats and 30% in dogs. Metabolic analysis shows species-specific differences: rats produce S- and N-oxidized metabolites, while dogs produce only N-oxidized metabolites. Sex-based pharmacokinetic differences were noted in rats but not in dogs. In vitro studies indicate cytochrome P450 (CYP) and flavin-containing monooxygenase (FMO) involvement in the sulfoxidation and N-oxidation of SNI-2011, with CYP2D and CYP3A mainly responsible for sulfoxidation in rat liver microsomes.
Smiles
C[C@H](SC1)O[C@]21CN3CCC2CC3.Cl.[0.5H2O]
Molecular Formula
C10H19ClNO1.5S
Molecular Weight
244.78
Shipping Conditions
Ice Packs
Storage Temperature
-20°C